Claims for Patent: 9,815,784

Summary for Patent: 9,815,784

Title:	CC-1065 analogs and their conjugates
Abstract:	This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
Inventor(s):	Beusker; Patrick Henry (Nijmegen, NL), Coumans; Rudy Gerardus Elisabeth (Nijmegen, NL), Elgersma; Ronald Christiaan (Nijmegen, NL), Menge; Wiro Michael Petrus Bernardus (Nijmegen, NL), Joosten; Johannes Albertus Frederikus (Nijmegen, NL), Spijker; Henri Johannes (Nijmegen, NL), de Groot; Franciscus Marinus Hendrikus (Nijmegen, NL)
Assignee:	Syntarga B.V. (Nijmegen, NL)
Application Number:	14/526,462
Patent Claims:	1. A compound of formula (III): ##STR00335## or a pharmaceutically acceptable salt thereof, wherein V.sup.2 is a full-length antibody or an antigen-binding fragment thereof; each L.sup.2 is independently absent or a linking group linking V.sup.2 to L; each L is independently absent or a linking group linking L.sup.2 to one or more V.sup.1 and/or Y; each V.sup.1 is a conditionally-cleavable or conditionally-transformable moiety, which can be cleaved or transformed by a chemical, photochemical, physical, biological, or enzymatic process; each Y is independently absent or a self-eliminating spacer system which is comprised of 1 or more self-elimination spacers and is linked to V.sup.1, optionally L, and one or more Z; each p and q are numbers representing a degree of branching and are each independently a positive integer; z is a positive integer equal to or smaller than the total number of attachment sites for Z; each Z is a compound of formula (I) ##STR00336## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is a leaving group, which is Cl; R.sup.2, R.sup.2', R.sup.4, R.sup.4', R.sup.12, and R.sup.19 are each H; X.sup.2 is C(R.sup.14)(R.sup.14'), wherein R.sup.14 has the same meaning as defined for R.sup.7 and R.sup.14' and R.sup.7' are absent resulting in a double bond between the atoms designated to bear R.sup.7' and R.sup.14'; R.sup.5, R.sup.6, and R.sup.7 are independently selected from the group consisting of H, OH, SH, NH.sub.2, N.sub.3, NO.sub.2, NO, CF.sub.3, CN, C(O)NH.sub.2, C(O)H, C(O)OH, halogen, R.sup.e, SR.sup.e, S(O)R.sup.e, S(O).sub.2R.sup.e, S(O)OR.sup.e, S(O).sub.2OR.sup.e, OS(O)R.sup.e, OS(O).sub.2R.sup.e, OS(O)OR.sup.e, OS(O).sub.2OR.sup.e, OR.sup.e, NHR.sup.e, N(R.sup.e)R.sup.f, .sup.+N(R.sup.e)(R.sup.f)R.sup.g, P(O)(OR.sup.e)(OR.sup.f), OP(O)(OR.sup.e)(OR.sup.f), SiR.sup.eR.sup.fR.sup.g, C(O)R.sup.e, C(O)OR.sup.e, C(O)N(R.sup.e)R.sup.f, OC(O)R.sup.e, OC(O)OR.sup.e, OC(O)N(R.sup.e)R.sup.f, N(R.sup.e)C(O)R.sup.f, N(R.sup.e)C(O)OR.sup.f, N(R.sup.e)C(O)N(R.sup.f)R.sup.g, and a water-soluble group, wherein R.sup.e, R.sup.f, and R.sup.g are independently selected from H and optionally substituted (CH.sub.2CH.sub.2O).sub.eeCH.sub.2CH.sub.2X.sup.13R.sup.e1, C.sub.1-15 alkyl, C.sub.1-15 heteroalkyl, C.sub.3-15 cycloalkyl, C.sub.1-15 heterocycloalkyl, C.sub.5-15 aryl, or C.sub.1-15 heteroaryl, wherein ee is selected from 1 to 1000, X.sup.13 is selected from O, S, and NR.sup.f1, and R.sup.f1 and R.sup.e1 are independently selected from H and C.sub.1-3 alkyl, one or more of the optional substituents in R.sup.e, R.sup.f, and/or R.sup.g optionally being a water-soluble group, two or more of R.sup.e, R.sup.f, and R.sup.g optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles, R.sup.5'+R.sup.6' are absent, resulting in a double bond between the atoms designated to bear R.sup.5' and R.sup.6'; X.sup.1 is O; wherein DB is selected from: ##STR00337## ##STR00338## R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.15, and R.sup.16 are each independently selected from the group consisting of H, OH, SH, NH.sub.2, N.sub.3, NO.sub.2, NO, CF.sub.3, CN, C(O)NH.sub.2, C(O)H, C(O)OH, halogen, R.sup.h, SR.sup.h, S(O)R.sup.h, S(O).sub.2R.sup.h, S(O)OR.sup.h, S(O).sub.2OR.sup.h, OS(O)R.sup.h, OS(O).sub.2R.sup.h, OS(O)OR.sup.h, OS(O).sub.2OR.sup.h, OR.sup.h, NHR.sup.h, N(R.sup.h)R.sup.i, .sup.+N(R.sup.h)(R.sup.i)R.sup.j, P(O)(OR.sup.h)(OR.sup.i), OP(O)(OR.sup.h)(OR.sup.i), SiR.sup.hR.sup.iR.sup.j, C(O)R.sup.h, C(O)OR.sup.h, C(O)N(R.sup.h)R.sup.i, OC(O)R.sup.h, OC(O)OR.sup.h, OC(O)N(R.sup.h)R.sup.i, N(R.sup.h)C(O)R.sup.i, N(R.sup.h)C(O)OR.sup.i, N(R.sup.h)C(O)N(R.sup.i)R.sup.j, and a water-soluble group, wherein R.sup.h, R.sup.i, and R.sup.j are independently selected from H and optionally substituted (CH.sub.2CH.sub.2O).sub.eeCH.sub.2CH.sub.2X.sup.13R.sup.e1, C.sub.1-15 alkyl, C.sub.1-15 heteroalkyl, C.sub.3-15 cycloalkyl, C.sub.1-15 heterocycloalkyl, C.sub.5-15 aryl, or C.sub.1-15 heteroaryl, one or more of the optional substituents in R.sup.h, R.sup.i, and/or R.sup.j optionally being a water-soluble group, two or more of R.sup.h, R.sup.i, and R.sup.j optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles, a is 0 and b is 1; wherein for each group that is optionally substituted, the substituent, when present, is selected from the group consisting of OH, .dbd.O, .dbd.S, .dbd.NR.sup.k, .dbd.N--OR.sup.k, SH, NH.sub.2, NO.sub.2, NO, N.sub.3, CF.sub.3, CN, OCN, SCN, NCO, NCS, C(O)NH.sub.2, C(O)H, C(O)OH, halogen, R.sup.k, SR.sup.k, S(O)R.sup.k, S(O)OR.sup.k, S(O).sub.2R.sup.k, S(O).sub.2OR.sup.k, OS(O)R.sup.k, OS(O)OR.sup.k, OS(O).sub.2R.sup.k, OS(O).sub.2OR.sup.k, S(O)N(R.sup.k)R.sup.l, OS(O)N(R.sup.k)R.sup.l, S(O).sub.2N(R.sup.k)R.sup.l, OS(O).sub.2N(R.sup.k)R.sup.l, OP(O)(OR.sup.k)(OR.sup.l), P(O)(OR.sup.k)(OR.sup.l), OR.sup.k, NHR.sup.k, N(R.sup.k)R.sup.l, .sup.+N(R.sup.k)(R.sup.l)R.sup.m, Si(R.sup.k)(R.sup.l)(R.sup.m), C(O)R.sup.k, C(O)OR.sup.k, C(O)N(R.sup.k)R.sup.l, OC(O)R.sup.k, OC(O)OR.sup.k, OC(O)N(R.sup.k)R.sup.l, N(R.sup.k)C(O)R.sup.l, N(R.sup.k)C(O)OR.sup.l, N(R.sup.k)C(O)N(R.sup.l)R.sup.m, a water-soluble group, and the thio derivatives of these substituents, and protonated, charged, and deprotonated forms of any of these substituents, wherein R.sup.k, R.sup.l, and R.sup.m are independently selected from H and optionally substituted --(CH.sub.2CH.sub.2O).sub.yyCH.sub.2CH.sub.2X.sup.17R.sup.yy, C.sub.1-15 alkyl, C.sub.1-15 heteroalkyl, C.sub.3-15 cycloalkyl, C.sub.1-15 heterocycloalkyl, C.sub.5-15 aryl, or C.sub.1-15 heteroaryl, or a combination thereof, wherein yy is selected from 1 to 1000, X.sup.17 is independently selected from O, S, and NR.sup.zz, and R.sup.zz and R.sup.yy are independently selected from H and C.sub.1-3 alkyl, two or more of R.sup.k, R.sup.l, and R.sup.m optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles, wherein the water-soluble group is selected from the group consisting of polyalcohols, straight chain or cyclic saccharides, primary, secondary, tertiary, or quaternary amines and polyamines, sulfate groups, sulfonate groups, sulfinate groups, carboxylate groups, phosphate groups, phosphonate groups, phosphinate groups, ascorbate groups, glycols, and polyethers; and each Z is independently connected to Y through either X.sup.1, an atom in R.sup.5, R.sup.6, R.sup.7, R.sup.14, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.15, R.sup.16, or an atom bearing any of these R substituents. 2. The compound according to claim 1 wherein and Y is connected to X.sup.1 via an .omega.-amino aminocarbonyl cyclization spacer being part of Y. 3. The compound according to claim 1 wherein V.sup.1 contains a substrate that can be cleaved by a proteolytic enzyme, plasmin, a cathepsin, cathepsin B, .beta.-glucuronidase, a galactosidase, prostate-specific antigen (PSA), urokinase-type plasminogen activator (u-PA), a member of the family of matrix metalloproteinases, or an enzyme localized by means of directed enzyme prodrug therapy; or wherein V.sup.1 contains a moiety that can be cleaved or transformed through reduction under hypoxic conditions, through reduction by a nitroreductase, or through oxidation. 4. The compound according to claim 1 wherein at least one L is present and such L is selected from ##STR00339## wherein rr, rr', and rr'' each independently range from 0 to 8, each X.sup.40 and X.sup.41 is independently selected from O, S, and NR.sup.135, wherein R.sup.135 is selected from H and C.sub.1-3 alkyl, and each uu, uu', and uu'' is independently selected from 0 and 1. 5. The compound according to claim 1 wherein at least one L.sup.2 is present and such L.sup.2 is ##STR00340## 6. The compound according to claim 1, which is ##STR00341## or an isomer, or a mixture of isomers, wherein R.sup.5, R.sup.6, R.sup.7, R.sup.14, and DB are as defined in claim 1, V.sup.1 is selected from valylcitrulline, valyllysine, phenylalanyllysine, alanylphenylalanyllysine, and D-alanylphenylalanyllysine, f is 1 or 2, L is selected from ##STR00342## q ranges from 1 to 20, rr, rr', and rr'' each independently range from 0 to 8, each X.sup.40 and X.sup.41 is independently selected from O, S, and NR.sup.135, wherein R.sup.135 is selected from H and C.sub.1-3 alkyl, and each uu, uu', and uu'' is independently selected from 0 and 1, and Ab is a full-length antibody or an antigen-binding fragment thereof. 7. The compound according to claim 1, which is ##STR00343## or an isomer, or a mixture of isomers, wherein R.sup.5, R.sup.6, R.sup.7, R.sup.14, and DB are as defined in claim 1, f' is 0, 1 or 2, g' is 0 or 1, V.sup.1' is selected from valylcitrulline, valyllysine, phenylalanyllysine, alanylphenylalanyllysine, and D-alanylphenylalanyllysine, L' is selected from ##STR00344## q' ranges from 1 to 20, rr, rr', and rr'' each independently range from 0 to 8, each X.sup.40 and X.sup.41 is independently selected from O, S, and NR.sup.135, wherein R.sup.135 is selected from H and C.sub.1-3 alkyl, each uu, uu', and uu'' is independently selected from 0 and 1, Ab is a full-length antibody or an antigen-binding fragment thereof, and V.sup.1 is selected from a mono-, di-, or oligosaccharide or a derivative thereof and ##STR00345## wherein R.sup.141, R.sup.142, and R.sup.143 are independently selected from H and optionally substituted C.sub.1-8 alkyl, C.sub.1-8 heteroalkyl, C.sub.3-8 cycloalkyl, C.sub.1-8 heterocycloalkyl, C.sub.5-8 aryl, or C.sub.1-8 heteroaryl. 8. The compound according to claim 1, which is ##STR00346## or an isomer, or a mixture of isomers, wherein R.sup.5, R.sup.6, R.sup.7, R.sup.14, and DB are as defined in claim 1, f' is 1 or 2, V.sup.1' is selected from valylcitrulline, valyllysine, phenylalanyllysine, alanylphenylalanyllysine, and D-alanylphenylalanyllysine, L' is selected from ##STR00347## q' ranges from 1 to 20, rr, rr', and rr'' each independently range from 0 to 8, each X.sup.40 and X.sup.41 is independently selected from O, S, and NR.sup.135, wherein R.sup.135 is selected from H and C.sub.1-3 alkyl, each uu, uu', and uu'' is independently selected from 0 and 1, Ab is a full-length antibody or an antigen-binding fragment thereof, and V.sup.1 is coupled to an atom of DB and is selected from a mono-, di-, or oligosaccharide or a derivative thereof and ##STR00348## wherein R.sup.141, R.sup.142, and R.sup.143 are independently selected from H and optionally substituted C.sub.1-8 alkyl, C.sub.1-8 heteroalkyl, C.sub.3-8 cycloalkyl, C.sub.1-8 heterocycloalkyl, C.sub.5-8 aryl, or C.sub.1-8 heteroaryl. 9. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier. 10. A method of treating or preventing a tumor in a mammal, which comprises administering a pharmaceutical composition according to claim 9 to the mammal in a therapeutically effective dose. 11. The compound according to claim 1, wherein DB is ##STR00349## 12. The compound according to claim 1, wherein DB is ##STR00350## ##STR00351## ##STR00352## ##STR00353## ##STR00354## ##STR00355## ##STR00356## 13. The compound according to claim 1, wherein V.sup.1 is phenylalanyllysine, valyllysine, or valylcitrulline. 14. The compound according to claim 1, wherein Y is selected from ##STR00357## wherein R.sup.117, R.sup.118, R.sup.119, and R.sup.120 are independently selected from the group consisting of H, OH, SH, NH.sub.2, N.sub.3, NO.sub.2, NO, CF.sub.3, CN, C(O)NH.sub.2, C(O)H, C(O)OH, halogen, R.sup.z, SR.sup.z, S(O)R.sup.z, S(O).sub.2R.sup.z, S(O)OR.sup.z, S(O).sub.2OR.sup.z, OS(O)R.sup.z, OS(O).sub.2R.sup.z, OS(O)OR.sup.z, OS(O).sub.2OR.sup.z, OR.sup.z, NHR.sup.z, N(R.sup.z)R.sup.z1, .sup.+N(R.sup.z)(R.sup.z1)R.sup.z2, P(O)(OR.sup.z)(OR.sup.z1), OP(O)(OR.sup.z)(OR.sup.z1), C(O)R.sup.z, C(O)OR.sup.z, C(O)N(R.sup.z1)R.sup.z2, OC(O)R.sup.z, OC(O)OR.sup.z, OC(O)N(R.sup.z)R.sup.z1, N(R.sup.z1)C(O)R.sup.z, N(R.sup.z1)C(O)OR.sup.z, and N(R.sup.z1)C(O)N(R.sup.z2)R.sup.z, wherein R.sup.z, R.sup.z1, and R.sup.z2 are independently selected from H and optionally substituted (CH.sub.2CH.sub.2O).sub.eeCH.sub.2CH.sub.2X.sup.13R.sup.e1, C.sub.1-20 alkyl, C.sub.1-20 heteroalkyl, C.sub.3-20 cycloalkyl, C.sub.1-20 heterocycloalkyl, C.sub.5-20 aryl, or C.sub.1-20 heteroaryl, wherein ee is selected from 1 to 1000, X.sup.13 is selected from O, S, and NR.sup.f1, and R.sup.f1 and R.sup.e1 are independently selected from H and C.sub.1-3 alkyl, two or more of R.sup.z, R.sup.z1, and R.sup.z2 optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles, and two or more of the substituents R.sup.117, R.sup.118, R.sup.119 and R.sup.120 optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles. 15. The compound according to claim 1, wherein L is selected from the group consisting of ##STR00358## ##STR00359## ##STR00360## 16. The compound according to claim 1, wherein said Ab is trastuzumab.

Details for Patent 9,815,784

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2028-11-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-11-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-11-03
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2028-11-03